Camurus 관리

관리 기준 확인 4/4

Camurus CEO는 Fredrik Tiberg, Jan2003 에 임명되었습니다 의 임기는 21.83 년입니다. 는 € 82.10M 가치에 해당하는 회사 주식의 2.82% 직접 소유합니다. 82.10M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 4.5 년입니다.

주요 정보

Fredrik Tiberg

최고 경영자

SEK 12.1m

총 보상

CEO 급여 비율	n/a
CEO 임기	21.8yrs
CEO 소유권	2.8%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Fredrik Tiberg 의 보수는 Camurus 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	SEK 266m
Jun 30 2024	n/a	n/a	SEK 223m
Mar 31 2024	n/a	n/a	SEK 450m
Dec 31 2023	SEK 12m	n/a	SEK 431m
Sep 30 2023	n/a	n/a	SEK 460m
Jun 30 2023	n/a	n/a	SEK 408m
Mar 31 2023	n/a	n/a	SEK 115m
Dec 31 2022	SEK 10m	SEK 6m	SEK 56m
Sep 30 2022	n/a	n/a	SEK 28m
Jun 30 2022	n/a	n/a	-SEK 13m
Mar 31 2022	n/a	n/a	-SEK 69m
Dec 31 2021	SEK 10m	SEK 6m	-SEK 90m
Sep 30 2021	n/a	n/a	-SEK 142m
Jun 30 2021	n/a	n/a	-SEK 156m
Mar 31 2021	n/a	n/a	-SEK 128m
Dec 31 2020	SEK 10m	SEK 5m	-SEK 167m
Sep 30 2020	n/a	n/a	-SEK 174m
Jun 30 2020	n/a	n/a	-SEK 216m
Mar 31 2020	n/a	n/a	-SEK 284m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 290m
Sep 30 2019	n/a	n/a	-SEK 305m
Jun 30 2019	n/a	n/a	-SEK 286m
Mar 31 2019	n/a	n/a	-SEK 266m
Dec 31 2018	SEK 8m	SEK 5m	-SEK 235m
Sep 30 2018	n/a	n/a	-SEK 200m
Jun 30 2018	n/a	n/a	-SEK 208m
Mar 31 2018	n/a	n/a	-SEK 187m
Dec 31 2017	SEK 6m	SEK 4m	-SEK 191m

보상 대 시장: Fredrik 의 총 보상 ($USD 1.11M ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 2.09M ).

보상과 수익: Fredrik 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Fredrik Tiberg (61 yo)

21.8yrs

테뉴어

SEK 12,056,000

보상

Mr. Fredrik Tiberg has been Independent Director of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. Mr. Tiberg serves as Chief Executi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Fredrik Tiberg	President	21.8yrs	SEK 12.06m	2.82% € 82.1m
Jon U. Alonso	Chief Financial Officer	2.8yrs	데이터 없음	0.0025% € 71.8k
Torsten Malmstrom	Chief Technology Officer	11.8yrs	데이터 없음	0.060% € 1.7m
Rein Piir	Vice President of Investor Relations	9.8yrs	데이터 없음	데이터 없음
Bo A. TarrasWahlberg	VP of Legal & Group General Counsel	less than a year	데이터 없음	데이터 없음
Maria Lundqvist	Global Head of Human Resources	3.6yrs	데이터 없음	데이터 없음
Markus Johnsson	Senior Vice President of R&D	no data	데이터 없음	0.036% € 1.0m
Fredrik Joabsson	Chief Business Development Officer	5.8yrs	데이터 없음	0.068% € 2.0m
Richard Jameson	Chief Commercial Officer	8.4yrs	데이터 없음	0.050% € 1.4m
Alberto Pedroncelli	Chief Medical Officer	1.4yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: 7CA 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Fredrik Tiberg	President	22.8yrs	SEK 12.06m	2.82% € 82.1m
Jakob Lindberg	Independent Director	3.5yrs	SEK 350.00k	데이터 없음
Per-Olof Wallstrom	Independent Chairman of the Board	14.8yrs	SEK 750.00k	0.17% € 5.1m
Behshad Sheldon	Independent Director	6.5yrs	SEK 350.00k	0.0017% € 49.4k
Hege Hellstrom	Independent Director	4.5yrs	SEK 375.00k	0.0055% € 160.8k
Stefan Persson	Director	2.5yrs	SEK 375.00k	0.0053% € 153.3k
Erika Johnsson	Director	1.5yrs	SEK 450.00k	0.0010% € 30.0k

4.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 7CA 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

Camurus 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Camurus AB (publ), Annual General Meeting, May 27, 2025

President recently sold €3.4m worth of stock

Chief Technology Officer recently sold €590k worth of stock

Camurus AB (Publ) Announces Board Resignations

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (publ), Annual General Meeting, May 08, 2024

Recent updates

Camurus AB (publ), Annual General Meeting, May 27, 2025

Third quarter 2024 earnings released: EPS: kr2.21 (vs kr1.56 in 3Q 2023)

Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025

Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly

President recently sold €3.4m worth of stock

Chief Technology Officer recently sold €590k worth of stock

Second quarter 2024 earnings released: EPS: kr1.28 (vs kr5.44 in 2Q 2023)

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings released: EPS: kr7.78 (vs kr1.01 in FY 2022)

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Full year 2023 earnings released: EPS: kr7.78 (vs kr1.01 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: kr1.56 (vs kr0.63 in 3Q 2022)

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: kr5.44 (vs kr0.15 in 2Q 2022)

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold €2.0m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

First quarter 2023 earnings released: EPS: kr1.06 (vs kr0.014 loss in 1Q 2022)

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

Full year 2022 earnings released: EPS: kr1.01 (vs kr1.66 loss in FY 2021)

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings released: EPS: kr0.15 (vs kr0.89 loss in 2Q 2021)

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

First quarter 2022 earnings released: kr0.01 loss per share (vs kr0.40 loss in 1Q 2021)

Camurus AB (Publ) Elects Stefan Persson as New Board Member

Full year 2021 earnings released: kr1.66 loss per share (vs kr3.18 loss in FY 2020)

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder

Forecast breakeven date pushed back to 2022

Camurus AB Announces Braeburn Receives New Complete Response Letter for Brixadi in the US

The European Medicines Agency Accepts Camurus's Application to Extend the Buvidal Indication to Include Treatment of Chronic Pain

Independent Chairman recently bought €85k worth of stock

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.38 loss in 3Q 2020)

Forecast to breakeven in 2021

Camurus AB (Publ) Announces FDA Grants Orphan Drug Designation in the US for CAM2029 for the Treatment of Polycystic Liver Disease

Camurus AB (Publ) Provides Earnings Guidance for the Year 2021

Camurus AB Announces Braeburn Resubmits New Drug Application for Brixadi in the US

Insider recently sold €186k worth of stock

Camurus Announces Publication Superior Patient Treatment Satisfaction with Buvidal® Weekly and Monthly Depot Injections in Opioid Dependence

First quarter 2021 earnings released: kr0.40 loss per share (vs kr1.19 loss in 1Q 2020)

Camurus Re-Affirms Financial Outlook for 2021

The Australian TGA Approves Key Label Updates to Camurus AB (publ)'s Buvidal® for Treatment of Opioid Dependence